The US Food and Drug Administration has approved halobetasol propionate foam, 0.05%, a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.
Morgan Ebert, Executive Editor
Advertisement
Morgan Ebert is executive editor Contemporary Pediatrics®. She joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio, before joining Contemporary Pediatrics. You can reach her at [email protected].
Articles by Morgan Ebert, Executive Editor
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves centanafadine for ADHD in children, adolescents, and adults
2
Omalizumab outperforms multiallergen oral immunotherapy in multifood allergy trial
3
Garadacimab demonstrates positive results in phase 3b trial for pediatric HAE prophylaxis
4
Pooled phase 3 data show early, consistent tapinarof cream responses across pediatric age groups in AD
5